Please do not leave this page until complete. This can take a few moments.
A biotechnology company working on a vaccine to prevent HIV, whose work is licensed by UMass Medical School in Worcester, has won U.S. Food and Drug Administration approval to advance its clinical work.
The firm, Worcester HIV Vaccine, was approved for the FDA's investigational new drug process for a vaccine that's aimed at preventing the virus that causes AIDS. An early-stage clinical trial is expected to start this month, with a second-phase trial to follow, the medical school said Friday.
The potential vaccine is based on discoveries by Dr. Shan Lu, a professor of medicine at UMass Medical School and licensed by the Worcester school. Worcester HIV Vaccine was founded more than two years ago, and the investigational drug approval by the FDA is a major achievement in its development, Yegor Veronin, the firm's COO, said in a statement.
Dr. Lu's lab at UMass has received more than $50 million in National Institute of Allergy and Infectious Diseases funding in the past 20 years to oversee the development and manufacturing of the vaccine, according to UMass.
“In order to stem the global tide of AIDS, finding an effective preventive HIV vaccine is our best hope of breaking the transmission cycle,” Dr. Lu said in a statement. “This brings promising new research into an HIV vaccine one step closer.”
Worcester HIV Vaccine is working with two partners on developing the vaccine: Wisconsin-based Waisman Biomanufacturing, a contract manufacturer helping to create the DNA substances used in the vaccine, and the Infectious Disease Research Institute in Seattle, which developed and manufactured the substance increasing the body's response to the vaccine.
The United States had 36,400 new HIV infections in 2018, according to the latest U.S. Department of Health & Human Services data. An estimated 1.2 million people nationwide have the virus, but one in seven don't know it. Worldwide, roughly 38 million had HIV in 2019, according to Department of Health & Human Services estimates.
Stay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Sign upWorcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
SubscribeWorcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
See Digital EditionStay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Worcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
Worcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments